AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2003_CD 81_CD 18_CD Financial_NNP instruments_NNS A_DT discussion_NN of_IN the_DT Groups_NNS objective_NN ,_, policy_NN and_CC strategy_NN in_IN respect_NN of_IN risk_NN management_NN and_CC the_DT use_NN of_IN financial_JJ instruments_NNS is_VBZ included_VBN in_IN the_DT Financial_NNP Review_NNP on_IN pages_NNS 31_CD to_TO 42_CD ._.
The_DT following_JJ disclosures_NNS exclude_VBP all_DT short_JJ term_NN ,_, trade_NN related_VBN debtors_NNS and_CC creditors_NNS ._.
Interest_NN rate_NN risks_NNS of_IN financial_JJ assets_NNS and_CC liabilities_NNS The_DT interest_NN rate_NN profile_NN ,_, after_IN taking_VBG into_IN account_NN interest_NN and_CC cross-currency_NN swaps_NNS ,_, of_IN the_DT financial_JJ assets_NNS and_CC liabilities_NNS of_IN the_DT Group_NNP as_IN at_IN 31_CD December_NNP 2003_CD was_VBD :_: Financial_NNP Weighted_NNP Weighted_NNP assets_NNS liabilities_NNS average_JJ average_NN on_IN which_WDT fixed_JJ period_NN for_IN Floating_VBG Fixed_VBN no_DT interest_NN is_VBZ interest_NN which_WDT rate_NN rate_NN rate_NN paid_VBD received_VBN Total_JJ rate_NN is_VBZ fixed_VBN $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD %_NN Years_NNS Financial_NNP liabilities_NNS US_NNP dollar_NN 430_CD 8_CD 438_CD 11.5_CD 9.7_CD Other_JJ 17_CD 17_CD 447_CD 8_CD 455_CD Financial_NNP assets_NNS US_NNP dollar_NN 3,542_CD 111_CD 3,653_CD Euro_NNP 8_CD 8_CD Sterling_NN 176 141 317_CD SEK_NNP 43_CD 22_CD 65_CD Other_JJ 128_CD 128_CD 3,897_CD 274_CD 4,171_CD The_DT floating_VBG rate_NN financial_JJ liabilities_NNS comprise_VBP largely_RB of_IN fixed_JJ rate_NN debt_NN that_WDT has_VBZ been_VBN swapped_VBN into_IN floating_VBG rate_NN debt_NN ._.
The_DT long_JJ dated_JJ $_$ 300m_CD US_NNP dollar_NN bond_NN reverts_VBZ back_RB to_TO a_DT fixed_JJ rate_NN in_IN 2009_CD ._.
The_DT financial_JJ liabilities_NNS also_RB include_VBP $_$ 152m_CD of_IN short_JJ term_NN bank_NN borrowings_NNS and_CC overdrafts_NNS ,_, bearing_VBG interest_NN at_IN rates_NNS fixed_VBN by_IN reference_NN to_TO local_JJ interbank_NN rates_NNS ._.
The_DT financial_JJ assets_NNS principally_RB comprise_VBP cash_NN on_IN overnight_JJ deposit_NN and_CC short_JJ term_NN investments_NNS with_IN an_DT average_JJ maturity_NN of_IN 29_CD days_NNS ._.
These_DT include_VBP deposits_NNS where_WRB the_DT interest_NN rate_NN is_VBZ fixed_VBN until_IN maturity_NN but_CC ,_, as_IN the_DT original_JJ maturity_NN is_VBZ less_JJR than_IN one_CD year_NN ,_, they_PRP are_VBP classified_VBN as_IN floating_VBG rate_NN financial_JJ instruments_NNS ._.
The_DT main_JJ benchmark_NN rates_NNS for_IN euro_NN and_CC US_NNP dollar_NN financial_JJ assets_NNS are_VBP the_DT relevant_JJ LIBID_NNP rates_NNS ._.
Financial_JJ assets_NNS include_VBP $_$ 220m_CD of_IN other_JJ fixed_JJ asset_NN investments_NNS on_IN which_WDT no_DT interest_NN is_VBZ received_VBN ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 82_CD Form_NN 20-F_JJ Information_NN 2003_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 18_CD Financial_NNP instruments_NNS continued_VBD Currency_NNP exposures_NNS 100_CD %_NN of_IN the_DT Groups_NNS major_JJ transactional_JJ currency_NN exposures_NNS on_IN working_VBG capital_NN balances_NNS ,_, which_WDT typically_RB extend_VBP for_IN up_RB to_TO three_CD months_NNS ,_, are_VBP hedged_VBN using_VBG forward_RB foreign_JJ exchange_NN contracts_NNS ._.
As_IN a_DT result_NN ,_, as_RB at_IN 31_CD December_NNP 2003_CD and_CC 31_CD December_NNP 2002_CD ,_, there_EX were_VBD no_DT material_NN monetary_JJ assets_NNS or_CC liabilities_NNS in_IN currencies_NNS other_JJ than_IN the_DT functional_JJ currencies_NNS of_IN the_DT Group_NNP companies_NNS concerned_VBN ,_, having_VBG taken_VBN into_IN account_NN the_DT effect_NN of_IN forward_RB exchange_NN currency_NN contracts_NNS that_WDT have_VBP been_VBN used_VBN to_TO match_VB foreign_JJ currency_NN exposures_NNS ._.
Additionally_RB ,_, in_IN 2003_CD and_CC 2002_CD ,_, approximately_RB 50_CD %_NN of_IN forecast_NN future_JJ foreign_JJ currency_NN transaction_NN exposures_NNS extending_VBG for_IN 12_CD months_NNS were_VBD selectively_RB hedged_VBN ._.
The_DT policy_NN has_VBZ been_VBN modified_VBN in_IN 2004_CD to_TO cover_VB movements_NNS outside_IN specified_VBN limits_NNS on_IN 95_CD %_NN of_IN these_DT transaction_NN exposures_NNS ._.
The_DT principal_JJ currency_NN exposures_NNS sterling_NN ,_, Swedish_JJ kronor_NNS SEK_NNP ,_, euros_NNS ,_, Australian_JJ dollars_NNS AUD_NNP ,_, Canadian_JJ dollars_NNS CAD_NNP and_CC Japanese_JJ yen_NNS were_VBD hedged_VBN using_VBG a_DT mixture_NN of_IN purchased_JJ currency_NN options_NNS and_CC forward_RB foreign_JJ exchange_NN contracts_NNS ._.
As_IN at_IN 31_CD December_NNP 2003_CD ,_, the_DT forecast_NN future_JJ foreign_JJ currency_NN transaction_NN exposures_NNS were_VBD :_: 2003_CD 2002_CD Forecast_NNP Forecast_NNP exposures_NNS exposures_NNS $_$ m_CD $_$ m_CD Sterling_NN payables_NNS 2,517_CD 2,374_CD SEK_NNP payables_NNS 1,422_CD 1,006_CD Euro_NNP receivables_NN 2,194_CD 1,780_CD Yen_NNP receivables_NN 444_CD 306_CD AUD_NNP receivables_NN 255_CD 201_CD CAD_NNP receivables_NN 482_CD 336_CD Maturity_NN of_IN financial_JJ liabilities_NNS The_DT maturity_NN profile_NN of_IN the_DT Groups_NNS financial_JJ liabilities_NNS ,_, other_JJ than_IN short_JJ term_NN creditors_NNS such_JJ as_IN trade_NN creditors_NNS and_CC accruals_NNS ,_, at_IN 31_CD December_NNP 2003_CD was_VBD as_IN follows_VBZ :_: 2003_CD 2002_CD Analysis_NN by_IN year_NN of_IN repayment_NN Loans_NNP Other_JJ Total_NNP Loans_NNPS Other_JJ Total_JJ $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD After_IN five_CD years_NNS 303 303 308 308_CD From_IN five_CD to_TO four_CD years_NNS 13_CD 13_CD From_IN four_CD to_TO three_CD years_NNS From_IN three_CD to_TO two_CD years_NNS From_IN two_CD to_TO one_CD years_NNS 7_CD 7_CD Due_JJ after_IN more_JJR than_IN one_CD year_NN 303 303 328 328_CD Due_JJ within_IN one_CD year_NN 152 152 314 328_CD 642 303 152 455_CD 642 328 970_CD Other_JJ financial_JJ liabilities_NNS comprise_VBP short_JJ term_NN borrowings_NNS and_CC ,_, at_IN 31_CD December_NNP 2002_CD ,_, deferred_VBN payments_NNS to_TO re-acquire_JJ certain_JJ distribution_NN rights_NNS ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP Form_NN 20-F_NNP Information_NNP 2003_CD 83_CD 18_CD Financial_NNP instruments_NNS continued_VBD Borrowing_NNP facilities_NNS The_DT Group_NNP currently_RB relies_VBZ on_IN its_PRP$ cash_NN balances_NNS and_CC short_JJ term_NN investments_NNS of_IN $_$ 3,742_CD m_NN and_CC long_JJ term_NN debt_NN of_IN $_$ 303m_CD to_TO manage_VB liquidity_NN risk_NN ._.
As_IN a_DT consequence_NN ,_, all_DT committed_JJ bank_NN lines_NNS have_VBP been_VBN canceled_VBN ._.
2003_CD 2002_CD $_$ m_CD $_$ m_CD Expiring_NN in_IN one_CD year_NN or_CC less_JJR 75_CD Expiring_NN in_IN more_JJR than_IN one_CD year_NN but_CC not_RB more_JJR than_IN two_CD years_NNS Expiring_VBG in_IN more_JJR than_IN two_CD years_NNS 75_CD Fair_NNP values_NNS of_IN financial_JJ assets_NNS and_CC financial_JJ liabilities_NNS Set_VBP out_RP below_IN is_VBZ a_DT comparison_NN by_IN category_NN of_IN carrying_VBG values_NNS and_CC fair_JJ values_NNS of_IN all_PDT the_DT Groups_NNS financial_JJ assets_NNS and_CC financial_JJ liabilities_NNS as_IN at_IN 31_CD December_NNP 2003_CD and_CC 31_CD December_NNP 2002_CD ._.
2003 2003 2002 2002_CD Carrying_VBG Fair_NNP Carrying_VBG Fair_NNP value_NN value_NN value_NN value_NN $_$ m_CD $_$ m_CD $_$ m_CD $_$ m_CD Primary_JJ financial_JJ instruments_NNS Short_JJ term_NN borrowings_NNS and_CC overdrafts_NNS 152 152 202 202_CD Loans_NNPS 303 371 657 733_CD Cash_NN 733 733 726 726_CD Short_JJ term_NN investments_NNS 3,218_CD 3,306_CD 3,962_CD 4,067_CD Fixed_VBN asset_NN investments_NNS 220_CD 217_CD 46_CD 46_CD Derivative_JJ financial_JJ instruments_NNS held_VBN to_TO manage_VB the_DT interest_NN rate_NN and_CC currency_NN profile_NN Cross-currency_NN swaps_NNS and_CC interest_NN rate_NN swaps_NNS 56_CD 15_CD 82_CD Derivative_JJ financial_JJ instruments_NNS held_VBN or_CC issued_VBN to_TO hedge_VB the_DT currency_NN exposure_NN on_IN existing_VBG transactions_NNS Forward_RB foreign_JJ exchange_NN contracts_NNS 12_CD 12_CD 9_CD 9_CD Derivative_JJ financial_JJ instruments_NNS held_VBN or_CC issued_VBN to_TO hedge_VB the_DT currency_NN exposure_NN on_IN expected_JJ future_JJ transactions_NNS Forward_RB foreign_JJ exchange_NN contracts_NNS 19_CD Foreign_JJ currency_NN option_NN contracts_NNS 77_CD 148_CD 56_CD 97_CD In_IN addition_NN to_TO the_DT primary_JJ financial_JJ instruments_NNS above_IN ,_, at_IN 31_CD December_NNP 2002_CD the_DT Group_NNP had_VBD financial_JJ liabilities_NNS of_IN $_$ 126m_CD comprising_VBG deferred_JJ payments_NNS due_JJ $_$ 129m_CD before_IN discounting_VBG ._.
The_DT Group_NNP had_VBD a_DT standby_JJ letter_NN of_IN credit_NN covering_VBG these_DT financial_JJ liabilities_NNS which_WDT was_VBD collateralised_VBN by_IN high_JJ grade_NN government_NN securities_NNS ._.
The_DT liabilities_NNS were_VBD settled_VBN in_IN 2003_CD and_CC the_DT standby_JJ letter_NN of_IN credit_NN canceled_VBN at_IN the_DT same_JJ time_NN ._.
AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 84_CD Form_NN 20-F_JJ Information_NN 2003_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 18_CD Financial_NNP instruments_NNS continued_VBD The_DT methods_NNS and_CC assumptions_NNS used_VBN to_TO estimate_VB the_DT fair_JJ values_NNS of_IN financial_JJ instruments_NNS are_VBP as_IN follows_VBZ :_: a._VB Short_JJ term_NN investments_NNS the_DT fair_JJ value_NN of_IN listed_VBN investments_NNS is_VBZ based_VBN on_IN year_NN end_NN quoted_VBN market_NN prices_NNS ._.
For_IN unlisted_JJ investments_NNS carrying_VBG values_NNS approximate_JJ fair_JJ value_NN ._.
Fixed_JJ asset_NN investments_NNS excluding_VBG equity_NN investments_NNS in_IN joint_JJ ventures_NNS and_CC associates_NNS the_DT fair_JJ value_NN of_IN listed_VBN investments_NNS is_VBZ based_VBN on_IN year_NN end_NN quoted_VBN market_NN prices_NNS ._.
c._FW Loans_NNPS the_DT fair_JJ value_NN of_IN publicly_RB traded_VBN debt_NN is_VBZ based_VBN on_IN year_NN end_NN quoted_VBN market_NN prices_NNS :_: the_DT fair_JJ value_NN of_IN floating_VBG rate_NN debt_NN is_VBZ nominal_JJ value_NN ,_, as_IN mark_NN to_TO market_NN differences_NNS would_MD be_VB minimal_JJ given_VBN frequency_NN of_IN resets_NNS :_: the_DT fair_JJ value_NN of_IN remaining_VBG debt_NN is_VBZ estimated_VBN using_VBG appropriate_JJ zero_CD coupon_NN valuation_NN techniques_NNS based_VBN on_IN rates_NNS current_JJ at_IN year_NN end_NN ._.
d._FW Forward_RB foreign_JJ exchange_NN contracts_NNS the_DT Group_NNP has_VBZ forward_RB foreign_JJ exchange_NN contracts_NNS to_TO sell_VB currency_NN for_IN the_DT purpose_NN of_IN hedging_VBG nondollar_JJ commercial_JJ transaction_NN exposures_NNS which_WDT existed_VBD at_IN the_DT date_NN of_IN the_DT balance_NN sheet_NN and_CC to_TO hedge_VB anticipated_VBN ,_, but_CC not_RB firmly_RB committed_VBN ,_, non-dollar_JJ commercial_JJ transactions_NNS for_IN 2004_CD ._.
The_DT majority_NN of_IN the_DT contracts_NNS for_IN existing_VBG transactions_NNS had_VBD a_DT maturity_NN of_IN six_CD months_NNS or_CC less_JJR from_IN year_NN end_NN ._.
The_DT fair_JJ value_NN of_IN forward_RB foreign_JJ exchange_NN contracts_NNS is_VBZ based_VBN on_IN market_NN forward_RB foreign_JJ exchange_NN rates_NNS at_IN year_NN end_NN ._.
e._FW Foreign_JJ currency_NN option_NN contracts_NNS the_DT Group_NNP has_VBZ foreign_JJ currency_NN option_NN contracts_NNS to_TO hedge_VB anticipated_VBN ,_, but_CC not_RB firmly_RB committed_VBN ,_, nondollar_JJ commercial_JJ transactions_NNS for_IN 2004_CD ._.
The_DT fair_JJ value_NN of_IN option_NN contracts_NNS is_VBZ estimated_VBN using_VBG Black-Scholes_NNP valuation_NN techniques_NNS as_IN adapted_VBN by_IN Garman_NNP and_CC Kohlhagen_NNP ._.
f._FW Interest_NN rate_NN and_CC cross-currency_NN swaps_NNS AstraZeneca_NNP uses_VBZ interest_NN rate_NN and_CC cross-currency_NN swaps_NNS to_TO hedge_VB the_DT Groups_NNS exposure_NN to_TO fluctuations_NNS in_IN interest_NN rates_NNS and_CC foreign_JJ exchange_NN movements_NNS on_IN borrowings_NNS in_IN accordance_NN with_IN a_DT formal_JJ risk_NN management_NN strategy_NN ._.
The_DT fair_JJ value_NN is_VBZ estimated_VBN using_VBG appropriate_JJ zero_CD coupon_NN valuation_NN techniques_NNS based_VBN on_IN rates_NNS current_JJ at_IN year_NN end_NN ._.
The_DT above_JJ financial_JJ instruments_NNS are_VBP subject_JJ to_TO credit_NN and_CC market_NN risk_NN ._.
AstraZeneca_NNP contains_VBZ credit_NN risk_NN through_IN the_DT use_NN of_IN counterparty_NN and_CC product_NN specific_JJ credit_NN limits_NNS and_CC by_IN ongoing_JJ review_NN procedures_NNS ._.
All_DT financial_JJ instruments_NNS are_VBP transacted_VBN with_IN commercial_JJ banks_NNS and_CC ,_, in_IN line_NN with_IN standard_JJ market_NN practice_NN ,_, are_VBP not_RB backed_VBN with_IN cash_NN collateral_NN ._.
The_DT notional_JJ principal_NN values_NNS of_IN off_JJ balance_NN sheet_NN financial_JJ instruments_NNS do_VBP not_RB represent_VB amounts_NNS exchanged_VBN by_IN the_DT parties_NNS and_CC are_VBP not_RB a_DT measure_NN of_IN the_DT credit_NN risk_NN to_TO the_DT Group_NNP of_IN these_DT instruments_NNS ._.
The_DT credit_NN risk_NN of_IN these_DT instruments_NNS is_VBZ limited_VBN to_TO the_DT positive_JJ fair_JJ values_NNS of_IN such_JJ contracts_NNS ._.
Market_NN risk_NN is_VBZ the_DT sensitivity_NN of_IN the_DT value_NN of_IN financial_JJ instruments_NNS to_TO changes_NNS in_IN related_JJ currency_NN and_CC interest_NN rates_NNS ._.
The_DT Group_NNP is_VBZ not_RB exposed_VBN to_TO material_NN market_NN risk_NN because_IN gains_NNS and_CC losses_NNS on_IN the_DT derivative_JJ financial_JJ instruments_NNS are_VBP largely_RB offset_VBN by_IN gains_NNS and_CC losses_NNS on_IN the_DT underlying_VBG assets_NNS ,_, liabilities_NNS and_CC transactions_NNS subject_JJ to_TO hedge_VB ._.
Hedges_NNP The_NNP Groups_NNS policy_NN was_VBD to_TO hedge_VB 100_CD %_NN of_IN transactional_JJ currency_NN exposures_NNS and_CC approximately_RB 50_CD %_NN of_IN forecast_NN future_JJ transaction_NN exposures_NNS using_VBG forward_RB foreign_JJ exchange_NN contracts_NNS and_CC foreign_JJ currency_NN option_NN contracts_NNS ._.
It_PRP also_RB uses_VBZ cross-currency_NN and_CC interest_NN rate_NN swaps_NNS to_TO manage_VB its_PRP$ borrowings_NNS profile_VBP ._.
Gains_NNS and_CC losses_NNS on_IN instruments_NNS used_VBN for_IN hedging_VBG are_VBP not_RB recognized_VBN until_IN the_DT exposure_NN that_WDT is_VBZ being_VBG hedged_VBN is_VBZ itself_PRP recognized_VBN ._.
Unrecognised_JJ gains_NNS and_CC losses_NNS on_IN instruments_NNS used_VBN for_IN hedging_VBG are_VBP as_IN follows_VBZ :_: Total_JJ net_JJ Gains_NNS Losses_NNS gains_VBZ $_$ m_CD $_$ m_CD $_$ m_CD Unrecognised_JJ gains_NNS and_CC losses_NNS on_IN hedges_NNS at_IN 1_CD January_NNP 2003 108 108_CD Gains_NNS and_CC losses_NNS arising_VBG in_IN previous_JJ years_NNS that_WDT were_VBD recognized_VBN in_IN 2003_CD 57_CD 57_CD Gains_NNS and_CC losses_NNS arising_VBG in_IN previous_JJ years_NNS that_WDT were_VBD not_RB recognized_VBN in_IN 2003_CD 51_CD 51_CD Unrecognised_JJ gains_NNS and_CC losses_NNS on_IN hedges_NNS at_IN 31_CD December_NNP 2003_CD 129_CD 21_CD 108_CD Gains_NNS and_CC losses_NNS expected_VBN to_TO be_VB recognized_VBN in_IN 2004_CD 89_CD 21_CD 68_CD Gains_NNS and_CC losses_NNS expected_VBN to_TO be_VB recognized_VBN in_IN 2005_CD or_CC later_RB 40_CD 40_CD
